Повидон-йод - новые возможности знакомого препарата (обзор литературы)
https://doi.org/10.25199/2408-9613-2021-8-3-12-18
Аннотация
В статье приведен обзор литературы, посвященной оценке эффективности, безопасности и показаниям к применению повидон-йода в современной клинической практике. Показаны сохранение хорошей чувствительности к препарату, несмотря на его многолетнее использование, а также новые возможности, связанные с эффективностью против биопленочных форм возбудителей и вирусов, в частности SARS-CoV-2.
Об авторе
И. В. Борисов
ФГБУ Национальный медицинский исследовательский центр хирургии им. А.В. Вишневского Минздрава России; ФГАОУ ВО Российский университет дружбы народов Минобрнауки России Россия
Россия
Россия
Игорь Викторович Борисов
117997, Москва, ул. Большая Серпуховская, д. 27; 117198, Москва, ул. Миклухо-Маклая, д. 8
Список литературы
1. Bigliardi P. L., Alsagoff S. A. L., El-Kafrawi H. Y., et al. Povidone iodine in wound healing: A review of current concepts and practices. Int J Surg. 2017; 44: 260-268.
2. Eggers M. Infectious Disease Management and Control with Povidone Iodine. Infect Dis Ther. 2019; 8 (4): 581— 593.
3. U.S. Patent N 2739922 Mixtures of Polymeric N-Vinil Pyrrolidone and Halogens. Shelanski H.A. Patented Mar. 27, 1956.
4. Barreto R., Barrois B., Lambert J., et al. Addressing the challenges in antisepsis: focus on povidone iodine. Intern J Antimicrobial Agents. 2020; 56 (3): 106064.
5. Punjataewakupt A., Napavichayanun S., Aramwit P. The downside of antimicrobial agents for wound healing. Eur J Clin Microbiol Infect Dis. 2019; 38 (1): 39—54.
6. Lachapelle J.-M., Castel O., Casado A. F., et al. Antiseptics in the era of bacterial resistance: a focus on povidone iodine. Clin Pract. 2013; 10(5): 579—592.
7. Percival S. L., McCarty S. M., Lipsky B. Biofilms and Wounds: An Overview of the Evidence. Adv Wound Care (New Rochelle). 2015; 4 (7): 373—381.
8. WHO. Fact sheet: Antimicrobial resistance (15 February 2018). Geneva: World Health Organization; 2018. Available from: https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resis-tance [accessed 4 February 2019].
9. Osterlund A., Eden T., Olsson-Liljeq-uist B., et al. Clonal spread among Swedish children of a Staphylococcus aureus strain resistant to fusidic acid. Scand J Infect Dis. 2002; 34 (10): 729—734.
10. Osterlund A., Kahlmeter G., Haegg-man S., Olsson-Liljequist B. Staphylococcus aureus resistant to fusidic acid among Swedish children: a follow-up study. Scand J Infect Dis. 2006; 38 (5): 334—334.
11. Carter G. P., Schultz M. B., Baines S. L., et al. Topical Antibiotic Use Coselects for the Carriage of Mobile Genetic Elements Conferring Resistance to Unrelated Antimicrobials in Staphylococcus aureus. Antimicrob Agents Chemother. 2018; 62(2): e02000—e02017.
12. Doudoulakakis A., Spiliopoulou I., Spyridis N., et al. Emergence of a Staphylococcus aureus Clone Resistant to Mu-pirocin and Fusidic Acid Carrying Exotoxin Genes and Causing Mainly Skin Infections. J Clin Microbiol. 2017; 55 (8): 2529—2537.
13. Kampf G. Acquired resistance to chlorhexidine —is it time to establish an ’antiseptic stewardship’ initiative. J Hosp Infect. 2016; 94 (3): 213—227.
14. Santajit S., Indrawattana N. Mechanisms of Antimicrobial Resistance in ES-KAPE Pathogens. Biomed Res Int 2016; 2016: 2475067.
15. Lacey R. W., Catto A. Action of povidone-iodine against methicillin-sensitive and -resistant cultures of Staphylococcus aureus. Postgrad Med J. 1993; 69 (Suppl 3): S78—S83.
16. Gilbert P., Moore L. E. Cationic antiseptics: diversity of action under a common epithet. J Appl Microbiol. 2005; 99 (4): 703—715.
17. Szostak K., Czogalla A., Przybylo M., Langner M. New lipid formulation of octenidine dihydrochloride. J Liposome Res. 2018; 28 (2): 106—111.
18. Wand M. E., Bock L. J., Bonney L. C., Sutton J. M. Mechanisms of Increased Resistance to Chlorhexidine and Cross-Resistance to Colistin following Exposure of Klebsiella pneumoniae Clinical Isolates to Chlorhexidine. Antimi-crob Agents Chemother. 2017; 61 (1): e01162-16.
19. Williamson D. A., Carter G. P., Howden B. P. Current and Emerging Topical Antibacterials and Antiseptics: Agents, Action, and Resistance Patterns. Clin Microbiol Rev. 2017; 30 (3): 827-860.
20. Sriwilaijaroen N., Wilairat P., Hira-matsu H., et al. Mechanisms of the action of povidone-iodine against human and avian influenza A viruses: its effects on hemagglutination and sialidase activities. Virol J. 2009; 6: 124.
21. McDonnell G., Russell A. D. Antiseptics and disinfectants: activity, action, and resistance. Clin Microbiol Rev. 1999; 12 (1): 147-179.
22. Pinto F., Maillard J. Y., Denyer S. P., McGeechan P. Polyhexamethylene bigu-anide exposure leads to viral aggregation. J Appl Microbiol. 2010; 108 (6): 18801888.
23. Schedler K., Assadian O., Brautferger U., et al. Proposed phase 2/ step 2 in-vitro test on basis of EN 14561 for standardised testing of the wound antiseptics PVP-io-dine, chlorhexidine digluconate, poli-hexanide and octenidine dihydrochloride. BMC Infect Dis. 2017; 17 (1): 143.
24. Berlanga M., Guerrero R. Living together in biofilms: the microbial cell factory and its biotechnological implications. Microb Cell Fact. 2016; 15 (1): 165.
25. Malone M., Bjarnsholt T., McBain A. J., et al. The prevalence of biofilms in chronic wounds: a systematic review and meta-analysis of published data. J Wound Care. 2017; 26 (1): 20-25.
26. Johani K., Malone M., Jensen S.O., et al. Evaluation of short exposure times of antimicrobial wound solutions against microbial biofilms: from in vitro to in vivo. J Antimicrob Chemother. 2018; 73 (2): 494-502.
27. Hoekstra M. J., Westgate S. J., Mueller S. Povidone-iodine ointment demonstrates in vitro efficacy against biofilm formation. Int Wound J. 2017; 14 (1): 172-179.
28. Gudapuri L. Cross-resistance between antiseptic agents and antimicrobial agents. Biom Biostat Int J. 2018; 7 (5): 429-430.
29. Jutkina J., Marathe N. P., Flach C. F., Larsson D. G. J. Antibiotics and common antibacterial biocides stimulate horizontal transfer of resistance at low concentrations. Sci Total Environ 2018; 616-617: 172-178.
30. Rothenberger J., Krauss S., Tschumi C., et al. The Effect of Polyhexanide, Octenidine Dihydrochloride, and Tea Tree Oil as Topical Antiseptic Agents on In Vivo Microcirculation of the Human Skin: A Noninvasive Quantitative Analysis. Wounds. 2016; 28 (10): 341-346.
31. Wang L., Qin W., Zhou Y., et al. Transforming growth factor beta plays an important role in enhancing wound healing by topical application of Povidone-iodine. Sci Rep. 2017; 7 (1): 991.
32. Kumar K. S., Reddy G.V., Naidu G., Pandiarajan R. Role of povidone iodine in periapical surgeries: Hemostyptic and anti-inflammatory. Ann Maxillofac Surg. 2011; 1 (1): 107-111.
33. Beukelman C. J., van den Berg A. J., Hoekstra M. J., et al. Anti-inflammatory properties of a liposomal hydrogel with povidone-iodine (Repithel) for wound healing in vitro. Burns. 2008; 34 (6): 845855.
34. Fumal I., Braham C., Paquet P., et al. The beneficial toxicity paradox of antimicrobials in leg ulcer healing impaired by a polymicrobial flora: a proof-of-concept study. Dermatology. 2002; 204 (Suppl 1): 70-74.
35. Pierard-Franchimont C., Paquet P., Arrese J. E., Pierard G.E. Healing rate and bacterial necrotizing vasculitis in venous leg ulcers. Dermatology. 1997; 194 (4): 383-387.
36. Muller G., Kramer A. Comparative study of in vitro cytotoxicity of povidone-iodine in solution, in ointment or in a liposomal formulation (Repithel) and selected antiseptics. Dermatology. 2006; 212 (Suppl 1): 91-93.
37. van Meurs S. J., Gawlitta D., Heems-tra K. A., et al. Selection of an optimal antiseptic solution for intraoperative irrigation: an in vitro study. J Bone Joint Surg Am. 2014; 96 (4): 285-291.
38. Кудыкин М. Н. Повидон-йод в основе лечения инфицированных ран. РМЖ. 2013; 34: 1755.
39. Родин А. В., Привольнев В. В., Савкин В. А. Применение повидон-йода для лечения и профилактики раневых инфекций в практике врача-хирурга. Амбулаторная хирургия. 2017; 3-4 (67-68): 43-51.
40. Чекмарева И. А., Блатун Л. А., Терехова Р. П. и др. Морфофункциональные аспекты регенерации ран при лечении йодсодержащими мазями. Хирургия. Журнал им. Н.И. Пирогова. 2014; (1): 54-58.
41. Лебедев Н. Н., Розанов В. Е., Шихметов А. Н. Алгоритм ведения больного с инфицированной раной в амбулаторных условиях с применением повидон-йода. Амбулаторная хирургия. 2018; 3-4 (7172): 51-56.
42. Барсуков А. Н., Агафонов О. И., Афанасьев Д. В. Применение повидон-йода в профилактике инфекций области хирургического вмешательства. РМЖ. Медицинское обозрение. 2018; (12): 7-11.
43. Dumville J. C., McFarlane E., Edwards P., et al. Preoperative skin antiseptics for preventing surgical wound infections after clean surgery. Cochrane Database Syst Rev. 2015; 2015 (4): CD003949.
44. Daroczy J. Antiseptic efficacy of local disinfecting povidone iodine (Betadine) therapy in chronic wounds of lymph-edematous patients. Dermatology. 2002; 204 (Suppl 1): 75-78.
45. Campbell N., Campbell D. Evaluation of a non-adherent, povidone-iodine dressing in a case series of chronic wounds. J Wound Care. 2013; 22 (8): 401-402, 404-406.
46. Woo K. Y. Management of non-heal-able or maintenance wounds with topical povidone iodine. Int Wound J. 2014; 11 (6): 622-626.
47. Блатун Л. А. Современные йодофоры — эффективные средства для профилактики и лечения гнойновоспалительных процессов в многопрофильном стационаре. Бюллетень ВСНЦ СО РАМН. 2005; (3): 200-202.
48. Блатун Л. А. Местное медикаментозное лечение ран. Хирургия. Журнал им. Н. И. Пирогова. 2011; (4): 51-59.
49. Lachapelle J. M. A comparison of the irritant and allergenic properties of antiseptics. Eur J Dermatol. 2014; 24 (1): 3-9.
50. Leung A. M., Braverman L. E. Consequences of excess iodine. Nat Rev Endocrinol. 2014; 10 (3): 136-142.
51. Godazandeh G., Qasemi N. H., SaghafiM., et al. Pleurodesis with povidone-iodine, as an effective procedure in management of patients with malignant pleural effusion. J Thorac Dis. 2013; 5 (2): 141144.
52. Kahrom H., Aghajanzadeh M., Asgari M.R., Kahrom M. Efficacy and Safety of Povidone-iodine Pleurodesis in Malignant Pleural Effusions. Indian J Palliat Care. 2017; 23 (1): 53-56.
53. Kovacikova L., Kunovsky P., Skrak P., et al. Thyroid hormone metabolism in pediatric cardiac patients treated by continuous povidone-iodine irrigation for deep sternal wound infection. Eur J Cardiothorac Surg. 2002; 21 (6): 1037-1041.
54. Whitehouse J. S., Gourlay D. M., Masonbrink A. R., et al. Conservative management of giant omphalocele with topical povidone-iodine and its effect on thyroid function. J Pediatr Surg. 2010; 45 (6): 1192-1197.
55. Yeginsu A., Karamustafaoglu A., Ozu-gurlu F., Etikan I. Iodopovidone pleurodesis does not effect thyroid function in normal adults. Interact Cardiovasc Thorac Surg. 2007; 6 (4): 563-564.
56. Caumes E., Le Maitre M., Garnier J.M., et al. Clinical tolerance of cutaneous antiseptics in 3,403 patients in France. Ann Dermatol Venereol. 2006; 133 (10): 755-760.
57. Su D., Zhao H., Hu J., et al. TRPA1 and TRPV1 contribute to iodine antiseptics-associated pain and allergy. EMBO Rep. 2016; 17 (10): 1422-1430.
58. Frank S., Brown S. M., Capriotti J. A., et al. In vitro efficacy of a povidone-iodine nasal antiseptic for rapid inactivation of SARS-CoV-2. JAMA Otolaryngol Head Neck Surg. 2020; 146(11): 1-5.
59. Kirk-Bayley J., Challacombe S., Sunkaraneni S., Combes J. The use of povidone iodine nasal spray and mouthwash during the current COVID-19 pandemic may protect healthcare workers and reduce cross infection. SSRN Electronic Journal. 2020.
60. Challacombe S. J., Kirk-Bayley J., Sunkaraneni V. S., Combes J. Povidone iodine. Br Dent J. 2020; 228(9): 656-657.
61. Stathis С., Victoria N., Loomis K., et al. Review of the use of nasal and oral antiseptics during a global pandemic. Review Future Microbiol. 2021; 16 (2): 119-130.
Рецензия
Для цитирования:
Борисов И.В. Повидон-йод - новые возможности знакомого препарата (обзор литературы). Раны и раневые инфекции. Журнал имени проф. Б.М. Костючёнка. 2021;8(3):14-20. https://doi.org/10.25199/2408-9613-2021-8-3-12-18
For citation:
Borisov I.V. Povidone iodine — new possibilities of a familiar dressing (literature review). Wounds and wound infections. The prof. B.M. Kostyuchenok journal. 2021;8(3):14-20. (In Russ.) https://doi.org/10.25199/2408-9613-2021-8-3-12-18
Просмотров: 728
Послать статью по эл. почте 